YUHSpace

BROWSE

Export

Cited 0 times in

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

DC Field Value Language
dc.contributor.author조병철-
dc.date.accessioned2024-10-04T02:44:55Z-
dc.date.available2024-10-04T02:44:55Z-
dc.date.issued2024-05-
dc.identifier.issn1525-7304-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/200583-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfCLINICAL LUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Monoclonal* / administration & dosage-
dc.subject.MESHAntibodies, Monoclonal* / therapeutic use-
dc.subject.MESHAntibodies, Monoclonal, Humanized* / administration & dosage-
dc.subject.MESHAntibodies, Monoclonal, Humanized* / therapeutic use-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols* / therapeutic use-
dc.subject.MESHB7-H1 Antigen* / antagonists & inhibitors-
dc.subject.MESHB7-H1 Antigen* / metabolism-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / pathology-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHLung Neoplasms* / pathology-
dc.subject.MESHMale-
dc.subject.MESHTreatment Outcome-
dc.titleA Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorEdward B Garon-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorAlexander Luft-
dc.contributor.googleauthorJorge Alatorre-Alexander-
dc.contributor.googleauthorSarayut Lucien Geater-
dc.contributor.googleauthorDmytro Trukhin-
dc.contributor.googleauthorSang-We Kim-
dc.contributor.googleauthorGrygorii Ursol-
dc.contributor.googleauthorMaen Hussein-
dc.contributor.googleauthorFarah Louise Lim-
dc.contributor.googleauthorCheng-Ta Yang-
dc.contributor.googleauthorLuiz Henrique Araujo-
dc.contributor.googleauthorHaruhiro Saito-
dc.contributor.googleauthorNiels Reinmuth-
dc.contributor.googleauthorMilena Kohlmann-
dc.contributor.googleauthorCaitlin Lowery-
dc.contributor.googleauthorHelen Mann-
dc.contributor.googleauthorSolange Peters-
dc.contributor.googleauthorTony S Mok-
dc.contributor.googleauthorMelissa L Johnson-
dc.identifier.doi38584069-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ03603-
dc.identifier.eissn1938-0690-
dc.identifier.pmid10.1016/j.cllc.2024.03.003-
dc.subject.keywordClinical trial-
dc.subject.keywordCytotoxic T-lymphocyte-associated antigen 4-
dc.subject.keywordImmune checkpoint inhibitor-
dc.subject.keywordImmunotherapy-
dc.subject.keywordProgrammed cell death ligand-1-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume25-
dc.citation.number3-
dc.citation.startPage266-
dc.citation.endPage273.e5-
dc.identifier.bibliographicCitationCLINICAL LUNG CANCER, Vol.25(3) : 266-273.e5, 2024-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Show simple item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links